Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study

BACKGROUND: Since the introduction of the combination treatment of anti-programmed death-ligand 1 antibody atezolizumab and anti-VEGF antibody bevacizumab (AB), median overall survival in HCC has drastically improved. However, evidence on the efficacy and safety of the novel treatment standard in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Joerg, Vincent, Scheiner, Bernhard, D´Alessio, Antonio, Fulgenzi, Claudia A.M., Schönlein, Martin, Kocheise, Lorenz, Lohse, Ansgar W., Huber, Samuel, Wege, Henning, Kaseb, Ahmed, Wang, Yinghong, Mathew, Antony, Kuang, Andrew, Muzaffar, Mahvish, Abugabal, Yehia I., Chamseddine, Shadi, Phen, Samuel, Cheon, Jaekyung, Lee, Pei-Chang, Balcar, Lorenz, Krall, Anja, Ang, Celina, Wu, Linda, Saeed, Anwaar, Huang, Yi-Hsiang, Bengsch, Bertram, Rimassa, Lorenza, Weinmann, Arndt, Stauber, Rudolf, Korolewicz, James, Pinter, Matthias, Singal, Amit G., Chon, Hong Jae, Pinato, David J., Schulze, Kornelius, von Felden, Johann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615429/
https://www.ncbi.nlm.nih.gov/pubmed/37889520
http://dx.doi.org/10.1097/HC9.0000000000000302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615429/
https://www.ncbi.nlm.nih.gov/pubmed/37889520
http://dx.doi.org/10.1097/HC9.0000000000000302

Ejemplares similares